Medichem, S.A.

medichem.es

Medichem, S.A. is an independently-owned Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) developer and manufacturer. Based in Barcelona (Spain), active in Malta and China, delivering medicines to over 60 markets across the world –including the U.S. and EU- Medichem is a fully-integrated pharmaceutical company with a unique portfolio of non-infringing APIs and FDFs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

news image

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

news image

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More

Pharma Tech

PHARMAKINNEX AND DATA360 TEAM UP TO EXTEND CLIENT REACH AND IMPROVE PATIENT ACCESS

PRNewswire | July 24, 2023

news image

PharmaKinnex (PK), an inside sales solution provider for the pharmaceutical industry, and Data360, a data and engagement solutions provider for healthcare marketers, today announced a strategic partnership to further enhance client reach and improve patient outcomes. From rare disease to oncology and beyond, this unique partnership is designed to deliver increased profits to clients, enable more advanced and secure data analysis, and most importantly, connect patients with life-...

Read More

Pharma Tech

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

news image

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More
news image

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More
news image

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More
news image

Pharma Tech

PHARMAKINNEX AND DATA360 TEAM UP TO EXTEND CLIENT REACH AND IMPROVE PATIENT ACCESS

PRNewswire | July 24, 2023

PharmaKinnex (PK), an inside sales solution provider for the pharmaceutical industry, and Data360, a data and engagement solutions provider for healthcare marketers, today announced a strategic partnership to further enhance client reach and improve patient outcomes. From rare disease to oncology and beyond, this unique partnership is designed to deliver increased profits to clients, enable more advanced and secure data analysis, and most importantly, connect patients with life-...

Read More
news image

Pharma Tech

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us